Semaglutide vs Cagrilintide

A GLP-1 receptor agonist originally approved for type 2 diabetes and now widely used for chronic weight management, producing 15%+ reductions in body weight over 12 months in clinical trials.

A long-acting amylin analogue developed by Novo Nordisk. On its own it produces modest weight loss; paired with semaglutide (CagriSema), it exceeds tirzepatide in trials.

Semaglutide mimics the incretin hormone GLP-1, slowing gastric emptying, reducing appetite via hypothalamic signalling, and enhancing glucose-dependent insulin secretion. The result is sustained calorie reduction without conscious restriction.

Cagrilintide activates amylin and calcitonin receptors, delaying gastric emptying and suppressing appetite through a mechanism complementary to GLP-1 receptor agonism.

0.25 mg weekly, titrated up to 2.4 mg weekly for weight loss

2.4 mg subcutaneous weekly (matched to semaglutide)

~7 days

~7 days

Subcutaneous once weekly, Oral (lower bioavailability)

Subcutaneous

approved

investigational

Not yet listed

Not yet listed